Amy Baxter
Staff ReporterAmy Baxter is a staff reporter for PharmaVoice. Before joining the team, she served as an editor and reporter in the B2B healthcare space for eight years at Health Exec and Home Health Care News. She also covered the retail industry as editor of Retail Leader, and hosted an Hermes award-winning weekly podcast and video interview series, Trend Talk, featuring industry executives and experts. A lifelong sailor, Amy has taken her media skills on the water to cover regattas and sailing events across the country. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Race to Mackinac Island. She is based in Florida.
75 articles by Amy Baxter
-
GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?
Dec. 11, 2024 -
A drug for fewer than 1,000 patients? Awareness and diagnosis are key.
Dec. 9, 2024 -
With Makary set to face FDA commissioner hearings, how deep do his industry ties run?
Dec. 4, 2024 -
Milk-based therapies could be coming. This biotech CEO is aiming to lead the way.
Dec. 2, 2024 -
Trump nominees want to slash and burn agencies. Will RFK Jr. and Oz do the same in healthcare?
Nov. 25, 2024 -
What might a Trump administration mean for the Biosecure Act?
Nov. 20, 2024 -
The first MASH drug could open the door for others — including GLP-1s
Nov. 18, 2024 -
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies
Nov. 13, 2024 -
What RFK Jr.’s influence could mean for pharma
Nov. 8, 2024 -
A diabetes drug, twice rejected, stumbles again — but its developer persists
Nov. 6, 2024 -
Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s
Nov. 4, 2024 -
2024 PharmaVoice 100s: Clinical Trial Pros
Oct. 31, 2024 -
Backlash builds against Novo’s Catalent takeover
Oct. 30, 2024 -
2024 PharmaVoice 100s: Tech and AI Wizards
Oct. 28, 2024 -
Where Big Pharma’s campaign cash is flowing in this election
Oct. 28, 2024 -
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
Oct. 21, 2024 -
2024 PharmaVoice 100s: Cardiometabolic All-Stars
Oct. 18, 2024 -
As election day nears, Trump and Harris veer in different directions on pharma
Oct. 14, 2024 -
How Madrigal plans to win on the market with the first MASH drug
Oct. 10, 2024 -
As AI transforms drug development, biotechs might not need as much Big Pharma support
Oct. 9, 2024 -
How Roche plans to fill a projected $8B sales gap
Oct. 2, 2024 -
FDA inspection backlog overseas threatens new drug approvals
Sept. 18, 2024 -
Biopharma prepares to pivot from China as Biosecure Act advances
Sept. 16, 2024 -
3 FDA approval dates to watch in the year’s final push
Sept. 11, 2024 -
Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies
Sept. 9, 2024